NCT00337493View on ClinicalTrials.gov

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

PHASE4CompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Kidney Transplantation

Interventions

DRUG

mycophenolate mofetil [CellCept]

Concentration-controlled

DRUG

mycophenolate mofetil [CellCept]

1g po bid

DRUG

Cyclosporine or tacrolimus

Reduced

DRUG

Cyclosporine or tacrolimus

Standard, as prescribed

Trial Locations (20)

14203

Buffalo

19104

Philadelphia

27599

Chapel Hill

30912

Augusta

32804

Orlando

35294

Birmingham

53792

Madison

58122

Fargo

60637

Chicago

71130

Shreveport

80262

Denver

90057

Los Angeles

97210

Portland

72205-7199

Little Rock

32610-0224

Gainesville

46202-5167

Indianapolis

40536-0293

Lexington

02111

Boston

07601

Hackensack

07039

Livingston

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00337493 - Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients. | Biotech Hunter | Biotech Hunter